Home Cart 0 Sign in  

[ CAS No. 185692-85-7 ] {[proInfo.proName]}

,{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]}
Chemical Structure| 185692-85-7
Chemical Structure| 185692-85-7
Structure of 185692-85-7 * Storage: {[proInfo.prStorage]}
Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Quality Control of [ 185692-85-7 ]

Related Doc. of [ 185692-85-7 ]

Alternatived Products of [ 185692-85-7 ]

Product Details of [ 185692-85-7 ]

CAS No. :185692-85-7 MDL No. :MFCD28403204
Formula : C14H31NO4Si Boiling Point : -
Linear Structure Formula :- InChI Key :OKOFEVZCVGPZCQ-NSHDSACASA-N
M.W : 305.49 Pubchem ID :11141286
Synonyms :

Calculated chemistry of [ 185692-85-7 ]

Physicochemical Properties

Num. heavy atoms : 20
Num. arom. heavy atoms : 0
Fraction Csp3 : 0.93
Num. rotatable bonds : 9
Num. H-bond acceptors : 4.0
Num. H-bond donors : 2.0
Molar Refractivity : 84.04
TPSA : 67.79 Ų

Pharmacokinetics

GI absorption : High
BBB permeant : Yes
P-gp substrate : Yes
CYP1A2 inhibitor : No
CYP2C19 inhibitor : No
CYP2C9 inhibitor : No
CYP2D6 inhibitor : No
CYP3A4 inhibitor : No
Log Kp (skin permeation) : -6.07 cm/s

Lipophilicity

Log Po/w (iLOGP) : 3.26
Log Po/w (XLOGP3) : 2.95
Log Po/w (WLOGP) : 2.89
Log Po/w (MLOGP) : 1.53
Log Po/w (SILICOS-IT) : 0.61
Consensus Log Po/w : 2.25

Druglikeness

Lipinski : 0.0
Ghose : None
Veber : 0.0
Egan : 0.0
Muegge : 0.0
Bioavailability Score : 0.55

Water Solubility

Log S (ESOL) : -3.0
Solubility : 0.307 mg/ml ; 0.001 mol/l
Class : Soluble
Log S (Ali) : -4.04
Solubility : 0.0281 mg/ml ; 0.000092 mol/l
Class : Moderately soluble
Log S (SILICOS-IT) : -2.93
Solubility : 0.358 mg/ml ; 0.00117 mol/l
Class : Soluble

Medicinal Chemistry

PAINS : 0.0 alert
Brenk : 1.0 alert
Leadlikeness : 1.0
Synthetic accessibility : 4.73

Safety of [ 185692-85-7 ]

Signal Word:Warning Class:N/A
Precautionary Statements:P280-P305+P351+P338 UN#:N/A
Hazard Statements:H302 Packing Group:N/A
GHS Pictogram:

Application In Synthesis of [ 185692-85-7 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Upstream synthesis route of [ 185692-85-7 ]
  • Downstream synthetic route of [ 185692-85-7 ]

[ 185692-85-7 ] Synthesis Path-Upstream   1~4

  • 1
  • [ 185692-85-7 ]
  • [ 51154-06-4 ]
Reference: [1] Journal of the Chemical Society - Perkin Transactions 1, 1999, # 15, p. 2155 - 2163
  • 2
  • [ 112418-19-6 ]
  • [ 185692-85-7 ]
YieldReaction ConditionsOperation in experiment
100%
Stage #1: With lithium borohydride In tetrahydrofuran at 20℃; for 2.5 h;
Stage #2: With ammonium chloride In tetrahydrofuran; water
To a solution of the product of Step 3 (16.5 g, 45.6 mmol) in THF (150 ml) wasadded 2M lithium borohydride in THF (37.1 ml) slowly. The mixture was stirred at RTfor 2.5 h. The reaction was quenched with saturated NH4CI and extracted with EtOAc(2x250 ml). The combined organic layer was washed with saturated NH4CI (100 ml),saturated sodium bicarbonate, and brine, dried, and concentrated to give the product(14.5 g, 100percent). MS m/e 306 (M+H)+
100% With lithium borohydride In tetrahydrofuran at 20℃; for 2.5 h; To a solution of the product of Step 3 (16.5 g, 45.6 mmol) in THF (150 ml) wasadded 2M lithium borohydride in THF (37.1 ml) slowly. The mixture was stirred at RTfor 2.5 h. The reaction was quenched with saturated NH4CI and extracted with EtOAc(2x250 ml). The combined organic layer was washed with saturated NH4CI (100 ml),saturated sodium bicarbonate, and brine, dried, and concentrated to give the product(14.5 g, 100percent). MS m/e 306 (M+H)+
Reference: [1] Patent: WO2006/14762, 2006, A1, . Location in patent: Page/Page column 42
[2] Patent: WO2006/14944, 2006, A1, . Location in patent: Page/Page column 32
[3] European Journal of Organic Chemistry, 2013, # 31, p. 7145 - 7151
[4] Journal of Medicinal Chemistry, 2015, vol. 58, # 10, p. 4204 - 4219
[5] Patent: WO2008/86122, 2008, A2, . Location in patent: Page/Page column 68
  • 3
  • [ 95715-85-8 ]
  • [ 185692-85-7 ]
Reference: [1] European Journal of Organic Chemistry, 2013, # 31, p. 7145 - 7151
[2] Journal of Medicinal Chemistry, 2015, vol. 58, # 10, p. 4204 - 4219
  • 4
  • [ 18162-48-6 ]
  • [ 185692-85-7 ]
Reference: [1] European Journal of Organic Chemistry, 2013, # 31, p. 7145 - 7151
Same Skeleton Products
Historical Records

Related Functional Groups of
[ 185692-85-7 ]

Organosilicon

Chemical Structure| 849767-21-1

[ 849767-21-1 ]

tert-Butyl 3-(((tert-butyldimethylsilyl)oxy)methyl)-4-oxopiperidine-1-carboxylate

Similarity: 0.67

Chemical Structure| 204580-28-9

[ 204580-28-9 ]

N-[2-(tert-Butyldimethylsilyloxy)ethyl]methylamine

Similarity: 0.61

Chemical Structure| 134756-75-5

[ 134756-75-5 ]

(S)-2-(((tert-Butyldimethylsilyl)oxy)methyl)pyrrolidine

Similarity: 0.58

Chemical Structure| 942190-60-5

[ 942190-60-5 ]

tert-Butyl 3-cyano-3-((trimethylsilyl)oxy)pyrrolidine-1-carboxylate

Similarity: 0.57

Chemical Structure| 76855-69-1

[ 76855-69-1 ]

(2R,3R)-3-((R)-1-((tert-Butyldimethylsilyl)oxy)ethyl)-4-oxoazetidin-2-yl acetate

Similarity: 0.57